~" The hypothesis that cerebral arteriovenous difference of oxygen content (AVDO2) can be used to predict cerebral blood flow (CBF) was tested in patients who were comatose due to head injury, subarachnoid hemorrhage, or cerebrovascular disease. In 51 patients CBF was measured daily for 3 to 5 days, and in 49 patients CBF was measured every 8 hours for 5 to 10 days after injury. In the latter group of patients, when a low CBF (~ 0.2 ml/gm/min) or an increased level of cerebral lactate production (CMRL) (_< -0.06 t~mol/gm/ min) was encountered, therapy was instituted to increase CBF, and measurements of CBF, AVDO2, and arteriovenous difference of lactate content (AVDL) were repeated. When data from all patients were analyzed, including those with cerebral ischemia and those without, AVDO2 had only a modest correlation with CBF (r = -0.24 in 578 measurements, p < 0.01). When patients with ischemia, indicated by an increased CMRL, were excluded from the analysis, CBF and AVDO2 had a much improved correlation (r = -0.74 in 313 measurements, p < 0.01). Most patients with a very low CBF would have been misclassified as having a normal or increased CBF based on the AVDO2 alone. However, when measurements of AVDO2 were supplemented with AVDL, four distinct CBF patterns could be distinguished. Patients with an ischemia/ infarction pattern typically had a lactate-oxygen index (LOI = -AVDL/AVDO2) of 0.08 or greater and a variable AVDO2. The three nonischemic CBF patterns had an LOI of less than 0.08, and could be classified according to the AVDO2. Patients with a normal CBF (mean 0.42 + 0.12 ml/gm/min) had an AVDO2 between 1.3 and 3.0 umol/ml. A CBF pattern of hyperemia (mean 0.53 + 0.18 ml/gm/min) was characterized by an AVDO2 of less than 1.3 t~mol/ml. A compensated hypoperfusion CBF pattern (mean 0.23 + 0.07 ml/gm/min) was identified by an AVDO2 of more than 3.0 umol/min. These studies suggest that reliable estimates of CBF may be made from AVDO2 and AVDL measurements, which can be easily obtained in the intensive care unit.
I N normal individuals, cerebral blood flow (CBF) is
closely coupled to and regulated by the cerebral metabolic rate of oxygen (CMRO2), which is calculated, by the Fick equation, from the product of the arterial-jugular venous oxygen difference (AVDO2) and the CBF (CMRO2 = AVDO2 X CBF). 11 Local CBF is increased or decreased depending on the tissue metabolic requirements. In certain altered physiological states, such as during seizures, changes in brain temperature, and anesthesia, CBF remains coupled to the CMRO2. 9 If the CMRO2 is decreased, by anesthesia for example, then CBF will also decrease since requirements for metabolic substrates are less. If the CMRO2 is increased, for example by fever, then CBF will also increase. Because the ratio between CMRO2 and CBF does not change if these parameters are normally coupled, the cerebral AVDO2 remains constant.
In patients in coma due to trauma or metabolic encephalopathy, CMRO2 is typically reduced from a normal value of 1.5 umol/gm/min to between 0.6 and
l, mol/gm/min. 7`j~
If CBF remains coupled to CMRO2, then CBF will also be reduced. Normal coupling of CBF is retained in only 45% of comatose headinjured patients, ~~ however; in most of these patients, the CBF regulatory mechanisms are abnormal and, rather than being coupled to CMRO2, CBF is increased or decreased independently of the reduced CMRO2. In this situation, the ratio between CMRO2 and CBF will vary. As CBF changes occur, measurements of the reciprocal changes in AVDOz might serve as an indicator of CBF adequacy. A normal AVDOz would suggest that CBF is normally coupled to CMRO2, a decreased AVDO2 would indicate that CBF is excessive for cerebral metabolic requirements, and an elevated AVDO: would indicate a decreased CBF. Figure 1 illustrates the nonlinear relationship between CBF and AVDO2 that would be expected in normal and pathophysiological conditions; a series of curves is displayed, each described by the formula: AVDO2 = CMRO# CBF. Each individual curve defines the relationship between AVDO~ and CBF that would occur if CMRO2 were held constant at a particular value and CBF were varied. The brain extracts oxygen more completely than most tissues, and the normal cerebral AVDO2, shown by the horizontal dashed lines in Fig. l , is 1.8 to 3.9 gmol/ml. 6 If a coupled change in CMRO2 and CBF occurs, then AVDO2 remains unchanged, and the relationship between CBF and AVDO~ simply shifts to a new CMRO2 curve, as illustrated by the horizontal arrows. Assuming that CMRO~ remains constant, changes in AVDO2 (curved arrows) reflect uncoupled variations in CBF. A low AVDO2 suggests that CBF is elevated relative to cerebral metabolic requirements, while an increased AVDO2 suggests that CBF is low. This hypothesis is of particular interest, because technology has become available to monitor cerebral AVDO2 continuously.* Such continuous monitoring of CBF adequacy may allow early identification and treatment of secondary ischemic injury.
Two conditions are obviously required for this hypothesis to be valid: CMRO~_ must be relatively constant and in the expected range; alternatively, if CMRO2 does change, there must be a marker that CMRO~_ has moved out of the expected range. Previous studies have shown * Monitoring system manufactured by Oximetrix, Inc., Mountain View, California. that when a head injury is accompanied by cerebral infarction, the first condition may not be true.' 2 In such cases, CMRO2 is typically less than 0.6 ~mol/gm/min in the presence of ischemic injury. However, these studies also showed that the characteristic elevation of cerebral lactate production may provide a satisfactory marker of the presence of significant cerebral ischemia, and therefore that CMRO2 may not be in the expected range.
The purpose of the present study was to assess the value of AVDO2 in predicting CBF and, in particular, in identifying patients with a low CBF.
Clinical Material and Methods

Patient Population and Management
From April 1, 1983 , to March 31, 1986, 51 patients who were admitted to Ben Taub General Hospital in coma (Glasgow Coma Scale score < 8) secondary to a head injury had measurements of CBF, CMRO2, and cerebral metabolic rate of lactate (CMRL) performed at least once a day for 3 to 5 days after injury. In the subsequent 22-month period, an additional 49 patients admitted in coma due to head injury, subarachnoid hemorrhage, or cerebrovascular disease had these parameters measured every 8 hours for the first 5 to 10 days after injury. The demographic characteristics of both groups of patients are shown in Table 1 .
All head-injured patients were treated by a standard protocol that emphasized early surgical evacuation of intracranial hematomas, controlled ventilation, and monitoring of intracranial pressure. Patients with subarachnoid hemorrhage were also treated by a standard protocol that included early clipping of aneurysms, with postoperative hypervolemic therapy guided by monitoring pulmonary wedge pressure. Routine medications included phenytoin, morphine for sedation, and antibiotics. Intracranial pressures greater than 20 mm Hg were treated with hyperventilation (pCO2 25 to 30 mm Hg), cerebrospinal fluid drainage, sedation and paralysis, mannitol, and (if necessary) barbiturates. Because of the marked effect of barbiturates on cerebral metabolism, CBF measurements obtained while patients were in barbiturate coma are not included in this analysis.
In the first group of patients, the presence of cerebral ischemia was identified retrospectively by the development of an infarction on computerized tomography as described in a previous study? 2 It became evident that focal cerebral ischemia could be identified in the presence of a normal global CBF by an elevated cerebral lactate production, so in the second group of patients cerebral ischemia was defined as a CBF of 0.2 ml/gm/ rain or below or a CMRL of -0.06 umol/gm/min or less. When changes characteristic of cerebral ischemia were found, treatments intended to increase CBF were undertaken. Treatments varied from patient to patient, but included allowing pCO2 to increase to 35 mm Hg, institution of hypervolemic hemodilution, and/or induction of hypertension by dopamine administration. The results of treatment were followed with repeated measurements of CBF, CMRO2, and CMRL. Treatment was considered successful if an increase in CMRO2 accompanied the improvement of CBF.
Cerebral Blood Flow
Cerebral blood flow was measured by the KetySchmidt technique, using N20 as the indicator. 4' 5"~7 A total of 578 individual CBF measurements were obtained, 174 in the first group of 51 patients and 404 in the second group of 49 patients. A No. 18 Teflon catheter was inserted percutaneously into the internal jugular vein and positioned so that the tip was in the jugular bulb. The catheter was placed on the side of the most severe injury, or on the right side if the injury was diffuse. The correct position of the catheter tip was confirmed by an x-ray study. A No. 20 catheter was placed in the radial artery. Ten percent N20 was introduced into the patient's inspired gases in a stepwise fashion, and l0 timed samples of arterial and jugular venous blood were anaerobically collected during the first 15 minutes of N20 saturation. The N20 concentration was measured in the blood samples on an infrared analyzert using an extraction system modified from that described by Swedlow and Lewis. 17 The CBF was calculated from curves fit to the measured N20 concentrations and integrated to 15 minutes (CBF-15) and to infinity. 4 The coefficient of variation of repeated CBF measurements was 3%. The CBF values are reported uncorrected for pCO2. Mean CBF measured by this method in a normal adult population is 0.5 ml/gm/ rain. 6 t Infrared N20 analyzer manufactured by Vital Signs, Inc., East Rutherford, New Jersey.
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Cerebral Metabolism
Arterial and jugular venous blood samples were obtained simultaneously with measurement of CBF for determination of blood gases, oxygen saturation, hemoglobin, and lactate concentration. The blood gases were measured on a Coming 165/2 or 170 blood gas analyzer and the hemoglobin and oxygen saturation on an IL-282 co-oximeter.~ Whole-blood lactate concentrations were measured by an enzymatic method or with a lactate analyzer.w
The CMRO2 and CMRL values were calculated by multiplying the CBF-15 by the AVDO2 and the arterialjugular venous difference of lactate (AVDL), respectively. As a measure of the ratio of the amount of glucose metabolized anaerobically to the amount metabolized aerobically, the lactate-oxygen index (LOI) was calculated by the formula, LOI = -AVDL]AVDO2. Although it does not accurately reflect the stoichiometry of glucose metabolism, the LOI is a simple calculation that does not require measurement of CBF or arteriovenous difference of glucose. The LOI value is normally less than 0.03. If CBF is decreased but cerebral oxygen consumption is maintained by increased extraction of oxygen, both AVDO2 and -AVDL will be increased and the LOI ratio will be unchanged. However, if increased oxygen extraction cannot compensate for the reduced CBF, then cerebral oxygen consumption will decrease, cerebral lactate production will increase, and the ratio LOI will be increased. In a previously reported series of patients, a LOI of 0.08 or more accurately predicted increased cerebral lactate production. ~2.~3
By the conventions used in this study, CMRO2 is a positive number, since there is always a net consumption of oxygen by the brain. In a normal adult, mean CMRO2 is 1.5 umol/gm/min/' The CMRL can be a positive or negative number, depending on whether there is a net uptake or excretion of lactate by the brain. Normally, there is a small but measurable cerebral lactate production (mean CMRL -0.02 #mol/gm/min). Elevated production of lactate by the brain is indicated by a more negative CMRL and by an increased LOI.
Statistical Analys&
All summary data are expressed as the mean _+ standard deviation. For the 578 measurements of CBF, the relationship between AVDO2 and CBF was analyzed by nonlinear regression analysis. For the patients who were identified as having developed cerebral ischemia, the CBF, CMRO2, and CMRL measured before and after treatment oftheischemia were compared by a paired t-test. A p value of < 0.05 was considered significant.
Blood gas analyzers manufactured by Ciba Coming Diagnostics Corp., Medfield, Massachusetts; co-oximeter manufactured by Instrumentation Laboratories, Lexington, Massachusetts.
w YSI-23L lactate analyzer manufactured by Yellow Springs Instruments, Yellow Springs, Ohio.
Results
When all 578 of the CBF measurements obtained in the 100 patients were examined, the expected nonlinear relationship between CBF and AVDO2 was found to be present (Fig. 2 ), but with a correlation coefficient of only -0.24 (p < 0.01). Most (72%) of the CMRO2 values fell between 0.6 and 1.2 ~zmol/gm/min, which was the expected range for patients with severe head injury. However, 112 (25%) of the CMRO2 values were less than 0.6 ~mol/gm/min. Only 12 (3%) of the values were over 1.2/~mol/gm/min. The patients with a very low CBF (_< 0.2 ml/gm/min) could not be identified by an elevated AVDO2 since their values ranged from 0.45 to 5.44 ~mol/ml. Most patients with a CBF of 0.2 ml/ gm/min or less would have been misclassified as having a normal or increased CBF if only the AVDO2 had been known.
When CBF measurements that were accompanied by an LOI of 0.08 or greater, indicating elevated cerebral lactate production, were excluded from the analysis, the correlation between CBF and AVDO2 was significantly improved (r --0 . 7 4 in 313 measurements, p < 0.01). As shown in Fig. 3 , most of the patients with very low CMRO2 values were eliminated by identifying elevated cerebral lactate production. In addition, the remaining patients without cerebral ischemia could be divided into three CBF categories by the level of their AVDO2. All of the patients with a CBF of 0.2 ml/gm/min or less had an AVDO2 over 3.0 #mol/ml. All of the patients with a very elevated CBF (> 0.8 ml/gm/min) had an AVDO2 of less than 1.3/~mol/ml.
From these data, a classification of CBF abnormalities was developed based on measurements of AVDO2 and AVDL. The mean values for CBF and CMRO2 in each CBF category are listed in Table 2 an AVDO2 of more than 3.0 t~mol/ml had a low CBF (mean 0.234 _ 0.069 ml/gm/min). Because this last category of patients did not have elevated cerebral lactate production or a CMRO2 of less than 0.6 umol/ gm/min, this CBF pattern was called "compensated hypoperfusion" rather than ischemia.
Because of the shape of the CMRO2 curves, AVDO2 was more sensitive for identifying patients with a low CBF. Small changes in CBF were associated with large changes in AVDO2 when CBF was low. There was considerable overlap in AVDO2 values between patients with a normal CBF and those with hyperemia. Nevertheless, increases in CBF in individual patients could be distinguished by changes in AVDO2. An example of findings in a patient with a temporal lobe contusion who developed a transient period of hyperemia is shown in Fig. 4 . During the time that the CBF was elevated, the CMRO2 was unchanged, and the CBF abnormality was evident from a decrease in AVDO> Eleven (22%) of the 49 patients who were evaluated for ischemia prospectively were found to have the characteristic changes of compensated hypoperfusion: decreased CBF and AVDO2 greater than 3.0 umol/ml, but a normal LOI. Their CBF averaged 0.221 +__ 0.038 ml/gm/min. One of the patients who had intracranial hypertension being managed with mechanical hyperventilation was treated by permitting the pCO2 to increase to 35 m m Hg. The other patients received hypervolemic hemodilution, and one was treated, in addition, with dopamine-induced hypertension. With treatment, all of the patients had an increase in CBF to a mean value of 0.336 ___ 0.050 ml/gm/min. In all cases, AVDO2 decreased into the normal range as CBF was increased by the therapy, from 3.92 --_ 0.84 to 2.61 _ 0.39 umol/ml (Fig. 5) . The CMRO2 was unchanged by the CBF treatment, confirming the conclusion based on the normal cerebral lactate production that these patients were not truly ischemic, but had been able to compensate for the low CBF by increased extraction of oxygen.
Four (7%) of the 49 patients studied prospectively for ischemia developed an ischemia/infarction CBF pattern after having an initially normal CBF. In one of the patients, the ischemia was due to severe intracranial hypertension that developed 24 hours after evacuation of a traumatic intracerebral hematoma. A second patient developed ischemia due to vasospasm 72 hours after a subarachnoid hemorrhage. The other two patients developed cerebral ischemia 2 to 3 days after closed head injury. Regardless of the etiology, all four patients changed from a pattern of normal CBF, with a normal AVDO2 and a normal cerebral lactate production, to a pattern of infarction (Fig. 6 ) between the routine CBF measurements (approximately 8 hours). The CBF dropped from 0.342 + 0.035 to 0.214 + 0.042 ml/gm/min, CMRO2 decreased from 0.76 + 0.09 to 0.18 + 0.13 ~tmol/gm/min, and cerebral lactate production increased from -0 . 0 2 0 _+ 0.017 to -0.042 + 0.007 ~tmol/gm/min. The AVDO~ decreased from 2.23 _+ 0.36 to 0.81 ___ 0.54 t~mol/ml, which, if interpreted alone, might suggest that CBF had increased. However, the LOI dramatically increased, from 0.03 + 0.02 to 0.36 +_ 0.29, indicating the presence of ischemia/infarction, and that AVDO2 would not accurately reflect CBF. In each case, a lateral skull x-ray film documented that the venous catheter remained in the jugular bulb; however, it cannot be ruled out that, with the drop in CBF, increased extracerebral contamination of the jugular venous blood might have accounted for the increase in venous oxygen saturation. Ten (20%) of the 49 patients evaluated for ischemia prospectively had an ischemic pattern on the initial CBF measurement or developed cerebral ischemia during their subsequent hospital course. In two patients in whom the cerebral ischemia was due to intractable intracranial hypertension, it was not possible to follow treatment of the ischemia with CBF measurements, because they died despite aggressive treatment. In the remaining eight patients, nine separate episodes of treatment of cerebral ischemia were documented with CBF measurements before and after treatment. The treatments that were examined included increasing pCO2 to 35 m m Hg (three patients), hypervolemic hemodilution (five patients), and dopamine-induced hypertension (one patient). In all nine cases, CBF increased with treatment from 0.163 ___ 0.038 to 0.303 _+ 0.107 ml/gm/min. With five of the episodes o f ischemia, an increase in CMRO2 accompanied the increase in CBF, from a mean value of 0.26 _ 0.17 to 0.68 _ 0.14 /zmol/gm/min (Fig. 7 upper) . In four patients, The relationship between CBF and the arteriovenous oxygen difference (AVDO2) is shown for the individual patients. The changes in AVDO2 as CBF increased were variable and not predictive of whether or not CMRO2 was improved.
CMRO2 remained unchanged, although CBF was increased by the therapy (Fig. 7 lower) . The change in AVDO2 was quite variable, and it was not possible to determine from the changes in AVDO2 whether CMRO2 was improved or not. However, the LOI decreased in the five episodes of cerebral ischemia where treatment resulted in an increase in CMRO2, and, in contrast, increased in the four patients in whom CMRO2 remained unchanged. Both of the patients whose CMRO2 did not change with treatment eventually died of their neurological injury. In the four patients in w h o m the improvement in CMRO2 was sustained for the remainder of the CBF monitoring, the LOI decreased to less than 0.08, clearly into the nonischemic range, while in the patient in whom the improvements in cerebral metabolism were transient despite continued treatment, the LOI decreased only from 0.45 to 0.13.
Discussion
From the data presented in this study, the model shown in Fig. 8 was developed. The model is based on the hypothesis, which was confirmed in this study, that in the absence of ischemia, CMRO2 is relatively constant in the comatose patient, typically ranging from 0.6 to 1.2 g m o l / g m / m i n , and CBF may vary independently of CMRO2. In these patients without ischemia, AVDO2 and CBF have the relationship represented by the constant CMRO2 curves. If CBF is in excess of cerebral metabolic requirements, AVDO2 will be de- creased. If CBF is decreased, AVDO: will proportionally increase as the brain compensates for the decreased flow by extracting a greater amount of oxygen. As long as increased extraction of oxygen completely compensates for the decreased blood flow, CMRO2 remains unchanged. However, a point will be reached at which further decreases in CBF cannot be compensated for by increased oxygen extraction and ischemia follows, manifested by a fall in CMRO2 and an increase in cerebral lactate production. Initially these metabolic changes of ischemia may be reversible. However, as time passes, irreversible ischemic injury or infarction may develop. The time required for the changes to become irreversible depends on the severity of the reduction in CBF. In experimental studies, a CBF of 0.18 ml/gm/min is tolerated for several hours before changes become irreversible, while a CBF of less than 0.10 ml/gm/min produces infarction in minutes. 2"3 As the tissue dies, CMRO2 falls, although cerebral lactate production may remain elevated. Increases in CBF after the tissue has become infarcted will not result in a significant increase in CMRO2, but instead will be expressed as a decrease in AVDO2.
In this series, it was u n c o m m o n to find a cerebral metabolic pattern that has been considered representative of early cerebral ischemia. ~ This pattern, characterized by a low CBF, an elevated AVDO2, and an increased cerebral lactate production, with an increase in CMRO2 and a decrease in cerebral lactate production on treatment of the low CBF, occurred on only one occasion in the 100 patients studied. Much more comm o n was a pattern of low CBF, an increased AVDO2, and a normal CMRL, which we have called "compensated hypoperfusion" or a pattern of low CBF, normal or decreased AVDO,, and an increased cerebral lactate production, which we have called "isehemia/infarction."
The compensated hypoperfusion pattern may be the most important to recognize clinically. The increased AVDO2 suggests that the brain is compensating for the decreased blood flow by extracting oxygen more completely, but because anaerobic metabolism is not increased and because CMRO2 does not change as CBF is increased, the low blood flow does not appear to have altered overall cerebral energy metabolism. Although the patients are not truly ischemic at the m o m e n t of the CBF measurement, they have exhausted the brain's compensatory mechanism for maintaining cerebral metabolism in the presence of decreased oxygen availability. In such cases, small decreases in either CBF or arterial oxygen content could produce significant cerebral ischemia.
The ischemia/infarction pattern is also important to identify, because sometimes this isehemia pattern is reversible. Because AVDO2 is low, this pattern is often assumed to indicate that brain tissue is irreversibly injured and that the CBF is adequate for the markedly reduced metabolic requirements. Although this is often the case, the presence of reversible isehemic changes are best determined by a trial of increasing CBF. The reason for the low AVDO2 in patients with reversible ischemia is not entirely clear. It m a y be that the blood flow is not homogeneous and that areas of very low flow and markedly increased oxygen extraction are mixed with areas of normal oxygen extraction. Alternatively, it may be that, with very low CBF, venous blood in the jugular bulb is contaminated with more extracerebral blood than when blood flow is normal. Studies conducted in normal adults have shown that extracerebral contamination is only 2% to 3%;15 however, no studies have documented that this remains the case when blood flow to the brain is markedly reduced.
Several factors could potentially affect the ability of the LOI to identify patients with ischemic injury. Other causes for cerebral lactic acidosis, such as ventriculitis, could cause an increase in the LOI in the absence of ischemia. Since the samples for AVDO~ and A V D L are obtained from only one internal jugular vein, the possibility exists of overlooking an infarction in brain tissue draining by the opposite jugular vein. Studies of oxygen and glucose concentrations performed on samples drawn simultaneously from both internal jugular veins have demonstrated small differences in normal adults, while marked differences can occur in patients with unilateral lesions.' Since the m o v e m e n t of lactate across the blood-brain barrier is dependent upon the relative concentrations of lactate in the brain tissue and in blood, an increase in cerebral lactate production could be obscured in the presence of a systemic lactic acidosis. 8'4 As long as arterial lactate concentration is normal, increases in cerebral lactate production should be reflected by a net effiux of lactate. In a previous study, an increased cerebral lactate production was present in patients that developed a cerebral infarction, even when arterial lactate concentration was increased. ~2
Although the underlying physiology of the injury is more easily understood if CBF measurements are available, reliable deductions about CBF can be made from measurements of AVDO2 and AVDL, which can be easily obtained in the intensive care unit. If the LOI is less than 0.08, cerebral ischemia is probably not present and CBF can be predicted reliably from the AVDO2. This permits identification of those patients with compensated hypoperfusion who may benefit from increasing CBF and of those patients with severe hyperemia. When the LOI is 0.08 or greater, ischemia or infarction is present, and the exact level of the CBF cannot be reliably predicted from the AVDO2. Actual measurement of CBF in this circumstance would be necessary. However, if treatment of the ischemia is successful in increasing CMRO2, the LOI will decrease, so that some clinically useful information can still be obtained without measuring CBF.
For future studies, continuous monitoring of jugular venous oxygen saturation, with periodic measurements of AVDO2 and AVDL, may be a valuable adjunct to intracranial pressure monitoring in comatose patients. A drop in jugular venous oxygen saturation or an increase in the LOI should trigger a search for causes of decreased oxygen delivery, such as a decrease in arterial pO2, hemoglobin, or CBF. Early identification and treatment of ischemic episodes may prevent secondary injury and improve overall outcome from neurological injury.
